Barely Significant
← all excerpts

[<sup>18</sup>F]Fluciclatide PET as a biomarker of response to combination therapy of pazopanib and paclitaxel in platinum-resistant/refractory ovarian cancer.

Eur J Nucl Med Mol Imaging · 2020 · PMC7101300 · PMID 31754793

Europe PMCDOI
1
hedged sentence
0.0800
closest p · 1.6× alpha
0.0800
boldest claim

The sentences

a negative trendp = 0.08so close (0.05 < p ≤ 0.1)
When considering the relationship between PET uptake parameters and PFS, a negative trend was observed between baseline SUV 60,mean and PFS (HR 1.75, 95%CI 0.93–3.30, p = 0.08).

also in 4,201 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.